Arrowhead to Present at Barclays Global Healthcare Conference
A live webcast of the presentation can be accessed by visiting the News & Events section of the company's website, http://www.arrowheadresearch.com/presentations .
Trending on the Topix Network
Thu Mar 06, 2014
Pre-Market Top Gainers Analysis: Smith & Wesson Holding, DryShips, Arrowhead Research and ZBB Energy
During the session gains in the Financials, Consumer Discretionary and Materials sectors positively impacted the broader market, while some retraction also came in from Energy, Utilities and Telecommunication Services sectors.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Arrowhead Research Corp. shares increased 24.46 percent to close at $26.31 a share Wednesday.
Wed Mar 05, 2014
Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit
Following the market opening Wednesday, the Dow traded down 0.04 percent to 16,388.82 while the NASDAQ declined 0.03 percent to 4,350.62.
Wall St. Cheat Sheet
3 Biotech Winners on Wednesday: Arrowhead, Osiris, Tekmira
Investors have seen the biotechnology momentum continue during Wednesday's trading session, with several biotechnology stocks producing significant gains.
The Motley Fool
Why Arrowhead Research Corp. Shares Surged
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research
Rating reports today from Deutsche Bank includes analyst Alethia Young initiating coverage on Arrowhead Research .
New Stock Coverage: Even Robin Hood Bows Down to Arrowhead Research
You will receive a download link right in your email inbox for each of the free reports that you choose.
's Top Initiations
Analysts at Barclays initiated coverage on shares of athenahealth with an "equal-weight" rating.
Mon Mar 03, 2014
Arrowhead Research Corporation Receives Regulatory Approval To Begin...
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus infection.
Thu Feb 20, 2014
Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST at the New York Palace Hotel.
Wed Feb 19, 2014
Judge Approves Lehman Brothers $767M Settlement; Arrowhead Research Hits New 52-week High
It was revealed earlier in the week that roughly 10,000 racist slurs are posted daily on Twitter , according to a group that sees value in analyzing the multitudinous chatter on social media .
Tue Feb 18, 2014
Customer Interaction Solutions
Arrowhead Announces Proposed Underwritten Offering of Common Stock
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
Mon Feb 10, 2014
Arrowhead Research Corp Director Sells $50,305 in Stock
Arrowhead Research Corp Director Edward W. Frykman unloaded 3,148 shares of the stock in a transaction dated Friday, February 7th.